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γδ T  cells are a minor population (~5%) of CD3 T  cells in the peripheral blood, but 
abound in other anatomic sites such as the intestine or the skin. There are two major 
subsets of γδ T cells: those that express Vδ1 gene, paired with different Vγ elements, 
abound in the intestine and the skin, and recognize the major histocompatibility complex 
(MHC) class I-related molecules such as MHC class I-related molecule A, MHC class 
I-related molecule B, and UL16-binding protein expressed on many stressed and tumor 
cells. Conversely, γδ T  cells expressing the Vδ2 gene paired with the Vγ9 chain are 
the predominant (50–90%) γδ T cell population in the peripheral blood and recognize 
phosphoantigens (PAgs) derived from the mevalonate pathway of mammalian cells, 
which is highly active upon infection or tumor transformation. Aminobisphosphonates 
(n-BPs), which inhibit farnesyl pyrophosphate synthase, a downstream enzyme of the 
mevalonate pathway, cause accumulation of upstream PAgs and therefore promote γδ 
T cell activation. γδ T cells have distinctive features that justify their utilization in antitumor 
immunotherapy: they do not require MHC restriction and are less dependent that αβ 
T cells on co-stimulatory signals, produce cytokines with known antitumor effects as 
interferon-γ and tumor necrosis factor-α and display cytotoxic and antitumor activities 
in vitro and in mouse models in vivo. Thus, there is interest in the potential application of 
γδ T cells in tumor immunotherapy, and several small-sized clinical trials have been con-
ducted of γδ T cell-based immunotherapy in different types of cancer after the application 
of PAgs or n-BPs plus interleukin-2 in vivo or after adoptive transfer of ex vivo-expanded 
γδ T cells, particularly the Vγ9Vδ2 subset. Results from clinical trials testing the efficacy 
of any of these two strategies have shown that γδ T  cell-based therapy is safe, but 
long-term clinical results to date are inconsistent. In this review, we will discuss the major 
achievements and pitfalls of the γδ T cell-based immunotherapy of cancer.
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iNTRODUCTiON
T  cells carrying the γδ T  cell receptor (TCR) are a minor 
lymphocyte population that accounts for 2–5% of CD3 T cells 
in the peripheral blood, but predominate in several anatomic 
sites such as the intestine and the skin. There are two major γδ 
T cell subsets in humans which are distinguished based on the 
δ chain they use to make their TCR: T cells expressing the Vδ2 
gene paired with the Vγ chain (Vγ9) are the great majority of 
the γδ T cell population in the peripheral blood and secondary 
lymphoid organs of healthy individuals. In contrast, γδ T cells 
expressing the Vδ1 gene, paired off with different Vγ elements, 
are the predominant γδ T  cell subset in epithelia (skin and 
mucosa). Finally, a third subset of γδ T cells expressing the Vδ3 
chain abound in the liver (1).
Vδ1 T cells have a largely private TCR repertoire with different 
clonotypes present in each individual, while the Vγ9Vδ2 reper-
toire has limited complexity with invariant Vγ9-JP sequences 
common to multiple individuals, and many CDR3δ2 sequences 
although are relatively private compared with TCRγ9 lengths, are 
shared between individuals (2, 3). Therefore, the Vγ9Vδ2 T cell 
population expresses a TCR with very limited variability, suggest-
ing recognition of a limited set of antigens.
Antigen recognition by γδ T cells is a field of intense research. 
Vγ9Vδ2 T  cells recognize non-peptidic phosphorylated inter-
mediates of the non mevalonate pathway of isoprenoid bio syn-
thesis called phosphoantigens (PAgs), in the absence of processing, 
presentation, and major histocompatibility complex (MHC) 
restriction (4). PAgs are synthesized in mammalian cells through 
the mevalonate pathway (5), but PAg concentrations required 
for Vγ9Vδ2 T  cell activation are not achieved in physiological 
conditions, but only after infections or tumor transformation 
(6). Therefore, from this point of view, the Vγ9Vδ2 TCR works 
in a similar way to a pattern-recognition receptor, which senses 
metabolic changes found in transformed or infected cells.
Intracellular PAg levels can be modulated by drugs. Thus, 
aminobisphosphonates (n-BPs) such as Zoledronate, widely 
used in the clinic for the treatment of osteoporosis and bone 
meta sta sis, inhibit farnesyl pyrophosphate synthase (FPPS), 
a down stream enzyme of the mevalonate pathway, thereby 
causing accumula tion of upstream PAgs and thus favoring 
Vγ9Vδ2 T cell activation (7, 8). Conversely, statins inhibit hydro-
xy-methylglutaryl-CoA reductase (HMGCR), the upstream 
enzyme of the mevalonate pathway, and significantly reduce 
PAgs production and Vγ9Vδ2 T cell activation (9).
Vδ1 T cells recognize MHC class I-related molecule A (MICA), 
MHC class I-related molecule B (MICB), and UL16-binding 
proteins (ULBPs) molecules, a group of proteins expressed on 
stressed and tumor cells (10, 11), and the MHC-related class 
Ib molecules CD1c and CD1d, which are typically involved in 
glycolipid presentation (12, 13). However, as Vδ1 T cells consti-
tutively express natural-killer group 2, member D (NKG2D), the 
“true” receptor of MICA and MICB, it is still to be determined if 
Vδ1 T cell recognition of MICA and MICB is mediated by the 
TCR or by NKG2D. Moreover, Vδ1 T cells can also be activated 
by engagement of natural cytotoxicity receptors (NCRs, such as 
NKp30 and NKp44) by yet unidentified ligands (14). Similar to 
Vδ1 T cells, Vδ3 T cell ligands are poorly unknown and there is 
only one study showing that these cells are activated by CD1d 
possibly bound to a yet unidentified glycolipid (15).
Phosphoantigens recognition by Vγ9Vδ2 T  cells requires 
butyrophilin (BTN) 3A1 (also called CD277) (16), but how 
PAgs interact with BTN3A1 and how the PAg/BTN3A1 complex 
in turn interacts with the Vγ9Vδ2 TCR is a matter of debate. 
Initial studies by Vavassori et al. (17) found a PAg-binding site 
located in the extracellular domain of BTN3A1, but a subsequent 
study by Adams and coworkers (18) found that PAgs bind to the 
intracellular domain of BTN3A1, leading to the possibility that 
intracellular PAgs provoke a conformational change of BTN3A1, 
which allows its extracellular domains to interact with the 
reactive Vγ9Vδ2 TCR.
Vγ9Vδ2 T  cells express several cell surface molecules cor-
related with distinct functional differentiation phenotypes. The 
combined use of CD27 and CD45RA permits identification of 
“naive” and “central memory” subsets of Vγ9Vδ2 T cells (TNaive, 
CD45RA+CD27+; TCM, CD45RA−CD27+) that circulate between 
the blood and secondary lymphoid organs, but are excluded 
from peripheral tissues and lack effector function; and “effector 
memory” (TEM, CD45RA−CD27−) and “terminally differentiated” 
(TEMRA, CD45RA+CD27−) subsets that circulate between the blood 
and peripheral tissues, are recruited to sites of inflammation 
and immediately perform effector function (19).
While TNaive and TCM cells readily respond to PAg stimulation, 
TEM and TEMRA respond to homeostatic cytokines as interleukin 
(IL)-15 (20) and may acquire highly diverse effector functions in 
the presence of polarizing cytokines (21). In general, circulating 
Vγ9Vδ2 T cells have a Th1 pattern of cytokine production (21), 
but under certain conditions they polarize to Th2 (22, 23), Th17 
(24–26), follicular T helper (27, 28), Th9 (29), and T regulatory 
(Treg) cells (30). Such a flexibility emphasizes the capacity of 
Vγ9Vδ2 T cells to efficiently participate to immune responses to 
different antigen challenges.
RATiONALe FOR HARNeSSiNG γδT 
CeLLS iN CANCeR iMMUNOTHeRAPY
In the following section, we will briefly summarize the rationale 
for harnessing γδ T cells in cancer immunotherapies.
 (1) The major objective of immunotherapy is the generation 
of a long-lasting efficient antitumor response, particularly 
mediated CD8 cytotoxic T cells, but also by CD4 T cells (31, 
32). Nonetheless, despite efforts, durable responses are only 
rarely achieved and moreover tumors often develop strate-
gies to escape immune responses (33). In contrast to CD4 
or CD8 T cells, γδ T cells have unique features which make 
them good candidates for effective tumor immunotherapy: 
they do not require MHC restriction and co-stimulation and 
they recognize antigens shared by a variety of stressed and 
tumor cells, making it possible for a single γδ T cell to target 
a vast array of tumor cells. Hence, recognition of commonly 
shared tumor antigens in the absence of MHC restriction 
provides the rationale for application of γδ T  cell-based 
FiGURe 1 | Tumor cell ligands recognized by human γδ T cells. The upper and lower panels show stimulatory and inhibitor signals delivered by tumor cells to Vδ1 
(left) and Vδ2 (right) γδ T cell subsets. Vγ9Vδ2 T cells recognize via their TCR non-peptidic phosphoantigens (PAgs) and BTN3A1, while Vδ1 T cell receptor (TCR) 
ligands are not defined yet. Both γδ T cell subsets constitutively express surface natural cytotoxicity cell receptors (NCRs) that bind MICA/MICB and ULBPs, 
frequently expressed on tumor cells. Upon activation, Vγ9vδ2 T cells express fragment crystallizable receptor for IgG (FcγRIII; also known as CD16) that can bind 
therapeutic antibodies and mediate antibody-dependent cell-mediated cytotoxicity phenomena. Inhibitor signals delivered by tumor cells have not been well 
characterized. MICA/B, MHC class I-related chain A/B; ULBP, UL16-binding protein; BTN3A1, butyrophilin 3A1.
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therapy to a wide range of tumors and in patients with dif-
ferent MHC molecules (34).
 (2) A distinctive feature of T lymphocytes equipped with anti-
tumor potential is their ability to secrete appropriate cyto-
kines. Typically, activated γδ T cells secrete interferon (IFN)-γ  
and tumor necrosis factor (TNF)-α, two cytokines with 
cytotoxic and antitumor activities (35–37).
 (3) A large body of studies have demonstrated that γδ T cells kill 
in vitro a broad array of tumor cells, while sparing normal 
cells (34), and display antitumor activity in mouse models 
in  vivo (34). The cytotoxic activity of γδ T  cells against 
tumor cells is strictly dependent on augmented production 
of PAgs (38), which partly relies on increased expression 
of HMGCR (38). Moreover, intracellular PAgs levels can 
be substantially increased by n-BPs (13–15, 38), thereby 
promoting activation of Vγ9Vδ2 T cells (38). Killing may 
also be reinforced by the tumor cell expression of NCRs 
(39) and/or NKG2D ligands (such as MICA, MICB, and 
ULBPs) (40–42) or by antibody-dependent cell-mediated 
cytotoxicity (ADCC) mediated by CD16 interacting with 
antibody-coated tumor cells (43) (Figure 1).
Whatever the mechanism of γδ T  cell recognition of 
tumor target cells, killing involves the perforin/granzyme 
(44) and TNF-related apoptosis-inducing ligand (TRAIL) 
(45) pathways, and Fas/FasL interaction (46). The choice 
of the mechanism is mostly dictated by the nature of the 
target cell itself (47). For instance, we previously found 
that colon cancer stem cells (CSCs), which are typically 
resistant to γδ T  cell-mediated cytotoxicity, are efficiently 
killed upon sensitization with Zoledronate (48). Killing of 
TABLe 1 | Survey of clinical trials based on in vivo activation of γδ cells.
Author Year Tumor Treatment Reference
Wilhelm et al. 2003 MM, NHL Pamidronate + IL-2 (58)
Dieli et al. 2003 Prostate, breast Zoledronate (8)
Dieli et al. 2007 Prostate Zoledronate/ 
Zoledronate + IL-2
(59)
Meraviglia et al. 2010 Breast Zoledronate + IL-2 (60)
Bennouna et al. 2010 Solid tumors BrHPP + IL-2 (61)
Gertner-
Dardenne et al.
2010 FBCL Rituximab +  
BrHPP + IL-2
(62)
Lang et al. 2011 RCC Zoledronate + IL-2 (63)
Kunzmann et al. 2012 RCC, MM, AML Zoledronate + IL-2 (64)
Pressey et al. 2016 Neuroblastoma Zoledronate + IL-2 (65)
MM, multiple myeloma; NHL, non-Hodgkin lymphoma; FBCL, follicular B-cell 
lymphoma; RCC, renal cell cancer; AML, acute myeloid leukemia; BrHPP, bromohydrin 
pyrophosphate; IL, interleukin.
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Zoledronate-treated colon CSCs was abrogated by anti-CD3 
or anti-γδ TCR monoclonal antibodies (mAbs), or mevas-
tatin, which inhibits HMGCR and prevents PAg accumula-
tion, and by Concanamycin A that blocks degranulation, 
indicating that Vγ9Vδ2 T  cells recognize Zoledronate-
treated colon CSCs by the TCR interacting with PAgs and 
utilize the perforin pathway to kill them (48). The colon 
CSCs are usually resistant also to chemotherapy, but we 
unexpectedly found that pretreatment with 5-Fluorouracil 
and Doxorubicin sensitizes colon CSCs to killing by Vγ9Vδ2 
T cells. However, killing of chemotherapy-sensitized colon 
CSCs by Vγ9Vδ2 T  cells was inhibited by anti-NKG2D 
mAb and by blocking TRAIL interaction with its death 
receptor 5 (DR5), indicating that Vγ9Vδ2 T cells recognize 
chemotherapy-treated colon CSCs by NKG2D interaction 
with MICA/B or ULBPs and kill them through mechanisms 
involving TRAIL interaction with DR5 (49).
 (4) In order for T lymphocytes to interact with tumor cells they 
should be capable to infiltrate tumors. Tumor-infiltrating 
leukocytes are found in a several different solid tumors (50) 
and include both myeloid (granulocytes, macrophages, and 
myeloid-derived suppressor cells) and lymphoid (T, B, and 
NK) cells, each of which impacts differently on tumor prog-
nosis (51). Tumor-infiltrating Vγ9Vδ2 T lymphocytes have 
been detected in several types of cancer (52), but their clinical 
relevance has remained long obscure because of inconsist-
ent results. However, analysis of expression signatures from 
~18,000 human tumors with overall survival outcomes across 
39 malignancies identified tumor-infiltrating γδ T cells as the 
most significant favorable cancer-wide prognostic signature 
(53). Similarly, our own results of data mining transcriptomes 
and clinical files from a large cohort of colorectal cancer sam-
ples (n = 585), revealed that the 5-year disease-free survival 
probability was significantly higher in patients with high 
number of tumor-infiltrating γδ T cells (54).
 (5) Two synthetic drugs, the PAg bromohydrin pyrophosphate 
(BrHPP) and the n-BP Zoledronate, activate human Vγ9Vδ2 
T lymphocytes in vitro and in clinical trials in vivo. BrHPP 
is produced as good manufacturing practice grade for use 
in humans under the name Phosphostim (55). Zoledronate, 
a third generation n-BP used to treat osteoporosis and 
bone metastasis, inhibits FPPS and causes accumulation of 
endogenous PAgs which thus reach the threshold required 
for Vγ9Vδ2 T cell activation (56). Second generation n-BPs, 
such as Pamidronate, Alendronate, and Risedronate, have 
similar activities of Zoledronate but at higher concentrations 
(55). Of note, in  vitro and in  vivo expansion of Vγ9Vδ2 
T cells by either PAgs or n-BPs requires exogenous IL-2.
Overall, the above functional aspects of γδ T cell biology, have 
led to their utilization in cancer immunotherapy, and two strate-
gies have been developed: (1) in vivo administration of PAgs or 
n-BPs that activate Vγ9Vδ2 T cells and (2) adoptive transfer of 
ex vivo-expanded Vγ9Vδ2 T  cells. Several small-sized phase I 
clinical trials have assessed the safety and efficacy of these two 
strategies in patients with various tumor types, and available 
data suggest that Vγ9Vδ2 T cell-based immunotherapy is well 
tolerated and may give some clinical benefit to patients, thus 
providing a proof of principle for its utilization in addition to 
conventional therapies (57).
In the following sections, we will review the major achieve-
ments and pitfalls of the Vγ9Vδ2 T cell-based immunotherapy.
ReSULTS FROM CLiNiCAL TRiALS BASeD 
ON IN VIVO ACTivATiON OF γδ T CeLLS
A survey of clinical trials based on in vivo activation of γδ T cells 
in different types of cancer is shown in Table 1.
Since B-cell type non-Hodgkin lymphoma (NHL) and 
multiple myeloma (MM) are highly sensitive to lysis by Vγ9Vδ2 
T cells in vitro, a pioneering study by Wilhelm and colleagues 
(58) analyzed in vivo the toxicity, Vγ9Vδ2 T cell activation and 
anti-lymphoma activity of Pamidronate and IL-2 in 19 patients 
with NHL or MM. Ten patients received Pamidronate followed 
by IL-2, but neither Vγ9Vδ2 T cell activation nor response to 
treatment were observed. Therefore, a second group of nine 
patients was selected for in  vitro Vγ9Vδ2 T  cell response to 
Pamidronate and IL-2 and was treated with Pamidronate fol-
lowed by increasing doses of IL-2. Significant in vivo expansion 
of Vγ9Vδ2 T cells was detected in this group, and three patients 
achieved objective responses. This was the first study demon-
strating activation of Vγ9Vδ2 T cells in patients with B-cell lym-
phomas by Pamidronate and low-dose IL-2 was well tolerated 
and induced a clinical response; moreover, the immunologic 
and clinical outcome could be nicely predicted by Vγ9Vδ2 T cell 
proliferation in vitro.
At the same time as the aforementioned study, we performed 
an observational study in nine cancer patients with bone 
metastases to determine if Zoledronate affected activation and 
maturation of circulating Vγ9Vδ2 T cells in vivo (8). The results 
of that study showed that Zoledronate-induced the in  vivo 
differentiation of Vγ9Vδ2 T cells to the TEM subset producing 
IFN-γ. Therefore, and based on this, we then conducted a phase 
I clinical trial in 18 patients with metastatic hormone-refractory 
prostate cancer (59). Patients were randomized into two groups, 
one receiving Zoledronate alone and the other receiving 
Zoledronate together with low-dose IL-2 subcutaneously (s.c.). 
TABLe 2 | Survey of clinical trials based on adoptive transfer of ex vivo-
expanded γδ cells.
Author Year Tumor Treatment Reference
Wada et al. 2014 Gastric 
cancer
Vγ9Vδ2 + Zoledronate (70)





RCC Vγ9Vδ2 + Zoledronate + IL-2 (66, 67)
Nicol et al. 2011 Solid 
tumors
Vγ9Vδ2 + Zoledronate (68)
Bennouna et al. 2008 RCC Vγ9Vδ2 + BrHPP + IL-2 (72)
Wilhelm et al. 2014 Vγ9Vδ2 + Zoledronate + IL-2 (69)
Nakajima et al. 2010 NSCLC Vγ9Vδ2 + Zoledronate + IL-2 (73)
Sakamoto et al. 2011 NSCLC Vγ9Vδ2 + Zoledronate + IL-2 (74)
MM, multiple myeloma; RCC, renal cell cancer; NSCLC, non-small cell lung cancer; 
BrHPP, bromohydrin pyrophosphate; IL, interleukin.
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The treatments were well tolerated and a significant clinical 
response was observed in the group receiving Zoledronate and 
IL-2 during the 1-year follow-up, which correlated with sus-
tained elevated numbers of blood Vγ9Vδ2 TEM cells producing 
IFN-γ and TRAIL.
We also conducted a phase I trial in 10 advanced metastatic 
breast cancer patients, using the same Zoledronate and IL-2 
regimen as in the above study (60), and found that 3 patients 
who sustained Vγ9Vδ2 T cell numbers achieved either disease 
stabilization (2 patients) or partial remission (1 patient).
While the above studies by the Wilhelm’s group and our 
group have used n-BPs and IL-2, Bennouna and colleagues (61) 
conducted a phase I trial using the synthetic PAg BrHPP with 
low doses of IL-2 in 28 patients with solid tumors. Patients first 
received BrHPP alone intravenously (i.v.) and then were treated 
with BrHPP i.v. in combination with IL-2 s.c. at weekly intervals. 
The BrHPP and IL-2 treatment was well tolerated and induced 
in vivo dose-dependent Vγ9Vδ2 T cell amplification. Based on 
these findings and the results from a preclinical study in macaques 
(62), Bennouna and colleagues conducted a multicentric phase II 
trial with BrHPP and IL-2 in 45 patients with follicular B-cell 
lymphoma who had been previously treated with the anti-CD20 
mAb Rituximab. The treatment provoked expansion of Vγ9Vδ2 
T lymphocytes in 39 out of the 45 patients, which peaked 1 week 
after the first injection of BrHPP, but declined upon subsequent 
injections. However, Vγ9Vδ2 T cells acquired the capability to 
produce IFN-γ and TNF-α and expressed FcγRIII (CD16) which 
promoted ADCC activity after the second and third injections 
of BrHPP. Clinical results from 38 patients consisted of 10 
instances of complete remission (CR) and 17 overall response 
rate. Therefore, administration of BrHPP, IL-2 and Rituximab 
produced very promising results, with limited side effects, over-
all supporting the potential of combining Vγ9Vδ2 T cell-based 
therapies with mAbs.
In contrast with these extremely promising results, two other 
phase I trials have confirmed that the Vγ9Vδ2 T  cell-based 
therapy is well tolerated, but have not shown evidence of anti-
tumor effects. Lang and colleagues (63) have conducted a phase 
I trial with Zoledronate and IL-2 in 12 patients with metastatic 
renal cell carcinoma. All patients experienced low grade adverse 
events, but no clinical response was observed. Rather, the treat-
ment induced a significant decrease of the in vitro Vγ9Vδ2 T cell 
proliferative response in the majority of the patients.
In another study, Kunzmann and coworkers (64) conducted 
a prospective phase I study with Zoledronate and IL-2 in 21 
patients with different advanced malignancies. The regimen was 
well tolerated and caused a marked in vivo activation and IFN-γ 
production of Vγ9Vδ2 T cells in all evaluable patients, but objec-
tive responses (partial remission) were observed only in two 
patients with acute myeloid leukemia. Interestingly, the lack of 
clinical response was associated with elevated pretreatment levels 
of serum vascular endothelial growth factor, which were even 
increased upon injection of Zoledronate and IL-2.
Finally, a recent prospective, non-randomized Phase I trial, 
has been conducted in nine young patients with refractory neu-
roblastoma, which has demonstrated that in vivo administration 
of Zoledronate and IL-2 s.c. can safely expand in vivo circulating 
Vγ9Vδ2 T cells, suggesting that intentional in vivo activation of 
Vγ9Vδ2 T cells might represent a strategy for the treatment of 
neuroblastoma (65).
ReSULTS FROM CLiNiCAL TRiALS BASeD 
ON ADOPTive TRANSFeR OF EX VIVO-
eXPANDeD γδ T CeLLS
Phase I clinical trials using adoptive transfer of ex vivo-
expanded γδ T cells have yielded somewhat conflicting results. 
A survey of these studies in different types of cancer is shown 
in Table 2.
Five studies have given results suggesting an antitumor effect 
of the therapy. Two trials were carried out by Kobayashi’s group 
in patients with advanced renal cell carcinomas; in one study 
(66), seven patients received Zoledronate-expanded Vγ9Vδ2 
T cells and IL-2 i.v. All patients had mild adverse events, four 
patients showed a significant in vivo expansion and IFN-γ pro-
duction by Vγ9Vδ2 T cells, but the clinical benefit was moder-
ate, as only three out of seven patients showed delayed tumor 
doubling time (66). In the second trial from the same group, all 
11 patients receiving Zoledronate-expanded Vγ9Vδ2 T cells and 
IL-2 showed prolonged tumor doubling time (67).
In another trial Nicol and coworkers (68) evaluated the 
safety and feasibility of the adoptive transfer of Vγ9Vδ2 T cells 
expanded ex vivo with Zoledronate and IL-2, in combination with 
Zoledronate given i.v. to 18 patients with advanced solid tumors 
who continued their previously ineffective chemotherapy. No 
toxicity was reported, and 3 out of the 18 patients had clinical 
responses (68). Interestingly, authors tracked Vγ9Vδ2 T  cells 
labeled with 111In in three patients. The cells localized to the lungs 
and remained there for 4–7 h after injection and then migrated 
to the liver and spleen. In one patient with a large metastasis in 
the left adrenal gland, the cells accumulated in the metastatic site 
1 h after injection and remained there until 48 h.
In a fourth trial, four patients with advanced hematological 
malignancies received haploidentical transplants (69) highly 
enriched for Vγ9Vδ2 T cells, followed by in vivo administration 
of Zoledronate and IL-2. Three patients showed CR during the 
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6-month follow-up, while one patient died of an infection 6 weeks 
after the cell transfusion.
Most recently, Wada and coworkers have conducted a pilot 
study in seven patients with neoplastic ascites caused by gastric 
cancer with Vγ9Vδ2 T cells expanded ex vivo with Zoledronate 
and IL-2, administered together with Zoledronate i.v. Weekly 
Intraperitoneal injection of Vγ9Vδ2 T cells had no severe adverse 
events and caused a significant reduction of the number of tumor 
cells in the ascites, which was evident soon after the first cycle 
of therapy and sustained over time. CT scan also revealed a 
significant reduction in volume of ascites in two out of the seven 
patients. Authors conclude that injection of Vγ9Vδ2 T cells can 
result in the control of malignant ascites in patients for whom 
no standard therapy is available (70).
In contrast to the above successful studies, several other phase 
I trials, while showing that Vγ9Vδ2 T  cell adoptive therapy is 
well tolerated, failed to providing evidence of antitumor effects.
Abe et al. (71) conducted a trial in six subjects with MM who 
received Zoledronate-expanded Vγ9Vδ2 T cells in combination 
with Zoledronate and IL-2. The treatment was safe but clinical 
efficacy, as assessed by M-protein serum levels remained at base-
line in four patients and increased in two patients, in the absence 
of between the number of Vγ9Vδ2 T cells injected and clinical 
outcome.
Bennouna et al. (72) conducted a phase I trial using ex vivo-
expanded Vγ9Vδ2 T cells in combination with BrHPP and IL-2, 
in 10 patients with metastatic renal cell carcinoma. Overall, the 
therapy was well tolerated with only one severe effect, 6 out of 
10 patients showed stable disease, but there was no significant 
antitumor effect.
Finally, in 2 studies of non-small cell lung cancer (NSCLC) 
involving 10 and 15 patients, respectively (73, 74), who received 
ex vivo-expanded Vγ9Vδ2 T cells and IL-2, there were no objec-
tive clinical responses although about one-third to one-half of 
the patients showed stable disease after therapy. In one study, 
Nakajima and coworkers (73) treated 10 patients with NSCLC 
with Vγ9Vδ2 T cells expanded ex vivo with Zoledronate and IL-2. 
The treatment was safe, three patients showed stable disease and 
five patients showed a progression of the disease 4 weeks after 
the last treatment. In the other study, Sakamoto and cowork-
ers (74) injected ex vivo-expanded γδ T  cells in patients with 
advanced NSCLC. Fifteen patients undergoing treatment with 
these γδ T cells did not have severe adverse events, all patients 
remained alive during the study period, but there were no 
objective responses.
wHAT DO THe γδ T CeLL-BASeD 
CLiNiCAL TRiALS TeACH US?
Clinical trials exploiting γδ T  cells in cancer have been con-
ducted over the past decade, with a good safety profile but 
variable efficacy. What is clear from these studies is that there 
is enormous variation in the types of cancer treated, combined 
with heterogeneity in the protocols used to expand γδ T  cells 
in  vivo or ex vivo for cellular immunotherapy, or in how the 
immunotherapy was delivered (e.g., PAgs or Zoledronate with 
or without IL-2, or in combination with other drugs, γδ T cells 
alone or in combination with activating drugs such as IL-2 
and Zoledronate). In addition, several factors may influence 
the success of γδ T  cell-based immunotherapy, which will be 
discussed in this section.
Immunotherapy strategy based on intentional activation of 
Vγ9Vδ2 T cells in vivo by administration of PAgs or n-BPs and 
IL-2 has been effective in activating circulating Vγ9Vδ2 T cells, 
but there is no evidence that this approach reaches tissue-resident 
γδ T cells or even promotes their recruitment at the tumor site, 
where they should in fact exert their antitumor activities.
Moreover, patients with several types of tumors have low 
numbers and unresponsive γδ T cells (75), even if more recent 
evidences indicate that reductions of γδ T  cell numbers and 
functions might be associated with age and sex and not with the 
presence of the tumor (76–78).
In addition, a decreased number of circulating Vγ9Vδ2 T cells 
have been observed as injections of PAgs or Zoledronate and 
IL-2 progressed, which was accompanied by a lower response of 
peripheral blood Vγ9Vδ2 T cells to PAgs.
The precise mechanism underlying this phenomenon remains 
unknown and further investigations are thus necessary. Among 
the possibilities, activation-induced Vγ9Vδ2 T cell anergy has 
been frequently reported (75), possibly due to inadequate sig-
nals delivered during activation, exposure to suboptimal PAgs 
concentration or from Vγ9Vδ2 T cell intrinsic features.
A recent clinical trial of Zoledronate given i.v. to cancer-
free patients showed that the inflammatory-type side effect of 
Zoledronate (flu-like syndrome) could be easily predicted by 
analyzing in vitro production of IFN-γ by Zoledronate-stimulated 
peripheral blood mononuclear cells (79). In agreement with 
these data, we and others have shown that repeated i.v. injec-
tions of Zoledronate was accompanied by decrease of circulating 
Vγ9Vδ2 TCM cells and reduction of their proliferative responses 
in vitro (79, 80). Circulating neutrophils may also contribute as 
they take up Zoledronate and produce hydrogen peroxide that 
inhibits T  cell proliferation (81). Finally, repeated stimulation 
of Vγ9Vδ2 T cells may also cause terminal differentiation and 
exhaustion (82–84).
Immunoevasion strategies can be exploited by cancer cells 
to escape recognition and attack by Vγ9Vδ2 T  cells. Indeed, 
several evidences demonstrate that cancer cells acquire the 
capability to inhibit immunological checkpoints using several 
different strategies. However, a very recent study has shown that 
Vγ9Vδ2 T cells express very low programmed death-1 (PD-1) 
compared with conventional αβ CD8 and CD4 T cells, which 
was markedly up-regulated over the first 4 days of exposure to 
Zoledronate and IL-2 in vitro but by day 7 dropped nearly to 
baseline (85). While these results suggest that Vγ9Vδ2 T cells 
may circumvent the PD-1/PD-1L checkpoint in  vivo, Hayday 
and coworkers found that Vγ9Vδ2 T cells express another nega-
tive checkpoint receptor, TIGIT, upon in vitro activation, thus 
providing an additional opportunity to cancer cells to escape 
Vγ9Vδ2 T  cell-mediated elimination (Hayday, unpublished 
results). Evasion strategies that specifically impair Vγ9Vδ2 
T cell functions can involve diverse immunosuppressive media-
tors produced in the tumor microenvironment, as, for example, 
FiGURe 2 | Strategies for γδ T cell-based immunotherapy. Actual strategies include adaptive cell transfer of γδ T cells expanded in vitro with Zoledronate and 
interleukin (IL)-2, and in vivo activation of Vγ9Vδ2 T cells by phosphoantigens [e.g., bromohydrin pyrophosphate (BrHPP)] or aminobisphosphonates (Zoledronate) 
and low-dose IL-2. Novel γδ T cell-based therapeutic strategies involve bispecific antibodies and CAR-T cells. ZA, Zoledronate acid; CAR, chimeric antigen 
receptors.
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transforming growth factor-β, prostaglandins, kynurenins, or 
potassium (86–89).
All of the above pitfalls may be partly overcome by utilization 
of the adoptive cell transfer of ex vivo-expanded Vγ9Vδ2 T cells, 
which thus seems to be a more effective procedure. However, 
the problem appears to be how to sustain the levels and func-
tions of the transferred Vγ9Vδ2 T cells. In metastatic renal cell 
carcinoma, two groups reported superior efficacy when Vγ9Vδ2 
T  cells were administered with Zoledronate and/or IL-2, as 
compared to Vγ9Vδ2 T cells administered alone (67, 90).
While the aforementioned trials utilized patients’ autologous 
peripheral blood-derived Vγ9Vδ2 T  cells, a recent study by 
Wilhelm and colleagues (69) utilized Vγ9Vδ2 T cells from hap-
loidentical donors; this treatment did not cause graft-versus-host 
disease and was clinically effective as three out of four patients 
achieved CR (69). Vγ9Vδ2 T cells from the haploidentical donor 
persisted for 28 days and expanded in vivo following injection 
of Zoledronate and IL-2.
Other studies have shown that it is possible to sustain injected 
Vγ9Vδ2 T cells without IL-2 supplementation, probably relying 
on IL-15 (91) or on IL-18 (92, 93) spontaneously produced by 
the host.
CAN we iMPROve γδ T CeLL-BASeD 
TUMOR iMMUNOTHeRAPY?
γδ T  cells can be redirected to the cancer cell using antibod-
ies (Figure  2). This can be achieved, for instance, by using 
bispecific antibodies, in which one binding site recognizes a 
tumor-specific cell surface molecule (for example, EpCAM or 
HER2/neu) and the other binding site targets CD3 or the Vγ9 
chain of the Vγ9Vδ2 TCR; such bispecific antibodies have been 
demonstrated effective in preclinical models (94, 95).
As a variant of the bispecific antibody technology, Zheng 
et  al. (96) prepared a chimeric molecule in which the variable 
portion derived from the extracellular domains of a Vγ9Vδ2 TCR 
(cloned from a Vγ9Vδ2 T cell infiltrating ovarian cancer) and the 
constant region was the fragment crystallizable (Fc) domain of 
human IgG1. This chimeric construct bound to several ovarian 
cancer cells, recognizing a yet unknown antigen and promoted 
the killing of the cells via ADCC mediated by binding of the Fc 
region of the chimeric construct to CD16.
Wesch and colleagues (97) developed recombinant immu-
noligands consisting of a CD20 single-chain variable fragment 
(scFv) linked to MICA or ULBP2 and found that both constructs 
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promoted the cytotoxic activity of ex vivo-expanded γδ T cells 
(containing both Vδ1 and Vδ2 T  cells) against CD20-positive 
lymphoma cells. Importantly, these two immunoligands medi-
ated the killing of chronic lymphocytic leukemia cells isolated 
from patients by γδ T cells, which was even enhanced by the PAg 
BrHPP. Thus, the utilization of recombinant immunoligands 
which engage NKG2D, with or without simultaneous TCR trig-
gering, may represent an attractive strategy to enhance antitumor 
cytotoxicity of γδ T cells.
Another approach consists in lentiviral-mediated transduc-
tion of T cells with chimeric antigen receptors (CARs; Figure 2). 
CARs are usually derived from scFvs of antibodies specific for 
tumor antigens, thus enabling the CAR-transduced T  cells to 
recognize tumor epitopes independently on their TCR [reviewed 
in Ref. (98)].
To date, most CAR utilize αβ T cells, but γδ T cells are also an 
appealing target, due to their antitumor effector functions.
Deniger et al. (99) have transduced polyclonal γδ T cells with 
a CD19-specific CAR which conferred the capability to efficiently 
kill CD19+ leukemia cells. The CAR technology has been com-
bined with the generation of induced pluripotent stem cells from 
human peripheral blood T cells (100). Such cells showed a very 
similar phenotype to γδ T cells and exerted antitumor activity.
T  cells can be redirected to tumors by lentiviral-mediated 
transduction with an exogenous TCR of known anticancer speci-
ficity, following adoptive transfer into patients. Typically, the vast 
majority of studies have involved transduction of an αβ TCR of 
well known antitumor specificity into another αβ T cell (101). 
The major problem with this strategy is the risk of mispairing 
between the endogenous and exogenous TCR α and β chains, 
resulting in receptors with autoreactive specificities (102, 103).
γδ T  cells offer an attractive solution to this problem, in the 
sense that a given tumor-specific αβ TCR can be introduced into 
γδ T  cells without the risk of mispairing (104, 105). Another 
advantage is that γδ T cells transduced with an αβ TCR retain the 
functionality of their original TCR, thereby responding rapidly 
upon antigen stimulation (106).
The main obstacle associated with the αβ TCR transfer, is that 
γδ T cells do not express CD4 or CD8 co-receptors, which are 
required for efficient recognition of peptide–MHC complexes on 
target cells. This implies that co-transduction with a co-receptor 
(107) or use of very high affinity TCRs (108) would be desirable 
to enhance antitumor activity of αβ-transduced γδ T cells. It is 
also possible to transduce peripheral lymphocytes (both γδ and 
αβ) with a specific γδ TCR, as successfully demonstrated by Zhao 
and coworkers (109, 110).
Finally all γδ T  cell-based clinical trials in patients with 
hematologic and solid tumors have relied on the utilization 
of Vγ9Vδ2 T  cells. Vδ1 T  cells are typically less susceptible to 
activation-induced exhaustion and in theory could persist long 
after adoptive transfer, providing the host with a durable antitu-
mor immune response (111). Moreover, as Vδ1 T cells express 
several NK receptors and possess a highly cytotoxic potential (8), 
they may constitute a potent therapeutic lymphocyte popula-
tion that could be exploited in alternative to, or in addition to 
Vγ9Vδ2 T cells. Accordingly, Silva Santos and coworkers (112) 
have recently developed a clinical-grade method to selectively 
expand Vδ1 T cells. The expanded Vδ1 T cells efficiently inhibited 
tumor growth and prevented dissemination in xenograft models 
of leukemia, thus providing a preclinical proof of principle for 
application of Vδ1 T cells in adoptive immunotherapy of cancer.
CONCLUSiON
Overall, studies performed to date have clearly demonstrated 
that γδ T cell-based tumor immunotherapy is safe, but clinical 
performance has been inconsistent (31). Identification of the 
ligands recognized by Vδ1+ and Vδ2+ T  cells, the antigen and 
cytokine requirements for their differentiation and survival, and 
the interactions they establish with tumor cells and other different 
components of the tumor microenvironment, will lead to a better 
understanding of how γδ T cells work and to properly harness 
these cells for effective and durable tumor immunotherapy.
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